Board of Directors

Wenche Rolfsen
Wenche Rolfsen
Chairman

Wenche Rolfsen has 30 years of experience in senior positions in preclinical research and development at Pharmacia. She was responsible for the early clinical organization at Quintiles Europe and CEO of Quintiles Scandinavia for a total of 11 years. She also has extensive experience from board positions in listed companies and is a member of the board of Swedish Match AB and Recipharm AB, among others.

Born: 1952
Education: Pharmacist, Doctor of Pharmacology, Adjunct Professor at Uppsala University.
Other current assignments: Wenche Rolfsen is chairman of the board of Sarsia Seed Fund, InDex Pharmaceuticals AB, InDex Pharmaceuticals Holding AB and board member of Swedish Match AB, Recipharm AB and InDex Diagnostics AB. Wenche Rolfsen is also CEO and board member of Rolfsen Consulting AB and partner in Serendipity Partners.
Prior assignments (past five years): During the last five years Wenche Rolfsen has been CEO of InDex Pharmaceuticals AB, chairman of the board of Aprea Therapeutics AB, Denator AB, Aprea Personal AB, Smartfish AB and board member of Moberg Pharma AB, TFS Trial Form Support International AB and Apotek Produktion & Laboratorier AB.
Holdings in the Company: Wenche Rolfsen owns 19,200 B-shares in the Company. Wenche Rolfsen has also acquired 1,818 call options from the Main Shareholders. The options entitle to the acquisition of 27,270 B-shares in the Company.

Independent in relation to the Company, its senior management and major shareholders.

Ivar Verner
Ivar Verner
Board member and deputy chairman

Ivar Verner is chairman of the board of Rejlers AB (publ) and former certified public accountant, partner and chairman of the board of Grant Thornton Sweden AB.

Born: 1947
Education: Master of Business Administration, Stockholm School of Economics
Other current assignments: Ivar Verner is chairman of the board of Rejlers AB (publ), Welcome Hotel i Sverige AB, Erlandssons Brygga AB, Erlandsons Brygga Sickla AB, Centrum Fastigheter i Norrtälje AB, Norrländska Gruppbostäder AB, Norrländska Gruppbostäder Holding AB, Tegnér & Son AB, EB Finans AB, Konditori Solsidan AB, Firren AB, Valsättra Exploaterings AB and Valsättra Villan AB. Verner is also board member of Förvaltningsaktiebolaget Kanalen, Sambo Fastigheter 2 AB, Constrera AB, Svenska Vårdfastigheter AB, Verner & Partners Förvaltning AB, Verner & Partners AB, Casa Firmus AB, Valsättra Tomter AB and deputy board member of Birgitta Verner Förvaltning AB. Ivar Verner is also general partner in the limited liability company Verner & Partners i Stockholm KB.
Prior assignments (past five years): During the past five years Ivar Verner has been chairman of the board of SpineMedical Sverige AB, SpineMedical AB, Ljungström & Andersson Invest AB, Dinami värme & vatten AB, Fastighets AB Kassaskåpet 4, Framtidsbolaget i Norrtälje AB and Norrforsen Kolartorp 1:84 AB. Verner has also been board member of Riksmalmen i Norrtälje AB, Centrumutveckling Sverige AB, Riksmalmen i Stockholm AB, Forex Bank AB and deputy board member of Svenska Vårdfastigheter AB. Verner has also been board member and liquidator of Ivar Verner Förvaltning AB and liquidator of Georg Helenius Construction AB, Restaurang Den Svarta Foten AB, Hollytree Förvaltning AB and Grönhögen Förvaltning AB.
Holdings in the Company: Ivar Verner owns, through the related company Förvaltningsaktiebolaget Kanalen AB, 72,500 B-shares in the Company. Ivar Verner has acquired 1,818 call options from the Main Shareholders. The options entitle to the acquisition of 27,270 B-shares in the Company.

Independent in relation to BioArctic, its senior management and major shareholders.

Hans Ekelund
Hans Ekelund
Board member

Hans Ekelund has an MBA from Stockholm School of Economics. He has had a number of assignments as board member and has previously been CFO of Ratos.

Born: 1948
Education: Master of Business Administration, Stockholm School of Economics
Other current assignments: Hans Ekelund is chairman of the board Connect Öst (non-profit association) and board member of Ekarna Invest AB.
Prior assignments (past five years): During the past five years Hans Ekelund has been chairman of the board of Minimarket Stockholm AB and chairman of the board and deputy board member of Wave Impact Heat Management AB. Ekelund has also been board member of SpineMedical Sverige AB and SpineMedical AB.
Holdings in the Company: Hans Ekelund owns, through the related company Ekarna Invest AB, 42,500 B-shares in the Company. Hans Ekelund has, through Ekarna Invest AB, acquired 1,818 call options from the Main Shareholders. The options entitle to the acquisition of 27,270 B-shares in the Company.

Independent in relation to the Company, its senior management and major shareholders.

Pär Gellerfors
Pär Gellerfors
Board member and Senior Vice President Business Strategy

Pär Gellerfors is together with Lars Lannfelt the founder of BioArctic. Gellerfors is Associate Professor of Biochemistry at Stockholm University. He is also co-founder of HemeBiotech/Zymenex A/S and has held several board memberships. Gellerfors is employed by the Company and responsible for business strategy. He is also co-opted member of the Senior management team.

Born: 1947
Education: Bachelor in chemistry at Stockholm University 1967; PhD in chemistry at Stockholm University 1977; Associate Professor of Biochemistry at Stockholm University 1983.
Other current assignments: Pär Gellerfors is CEO and board member of Swenora Biotech AB, board member of Ackelsta AB, LPB Sweden AB and LPB Sweden Holding AB and deputy board member of Otwomed AB.
Prior assignments (past five years): During the past five years Pär Gellerfors has been CEO of BioArctic AB, CEO and board member of GPM Medical AB, SpineMedical Sverige AB and SpineMedical AB, board member of Hogholmen Förvaltning AB, Hogholmen AB and deputy board member of MILIDA AB.
Holdings in the Company: Pär Gellerfors owns, through the wholly-owned company Ackelsta AB, a total of 5,759,998 A-shares and 15,232,989 B-shares in the Company.

Dependent in relation to the Company, its senior management and in relation to major shareholders.

Lars Lannfelt
Lars Lannfelt
Board member

Lars Lannfelt is together with Pär Gellerfors the founder of BioArctic. Lannfelt is Senior Professor at Uppsala University and also a member of The Royal Swedish Academy of Sciences.

Born: 1949
Education: Medical degree 1978; specialist in psychiatry 1987; doctoral thesis at Karolinska Institutet 1990; Associate Professor of Neurogenetics at Karolinska Institutet 1993; specialist in geriatrics 2000; Professor of Geriatrics at Uppsala University 2001; Senior Professor at Uppsala University 2016.
Other current assignments: Lars Lannfelt is board member of Demban AB.
Prior assignments (past five years): During the past five years Lars Lannfelt has been board member of Demban Förvaltning AB, SpineMedical Sverige AB and SpineMedical AB. Lannfelt has also been partner in Bild & Forskning L & L handelsbolag.
Holdings in the Company: Lars Lannfelt owns, through the wholly-owned company Demban AB, a total of 8,639,998 A-shares and 22,848,159 B-shares in the Company.

Dependent in relation to BioArctic, its senior management and in relation to major shareholders.

Eugen Steiner
Eugen Steiner
Board member

Eugen Steinar has 30 years experience of leading life science companies. Prior to that he was active as a doctor at Karolinska Hospital (Huddinge) and a researcher at Karolinska Institutet. As a venture partner to HealthCap since 1997, he has been CEO of certain companies in which HealthCap has invested. He has extensive experience from board positions in Sweden, Norway, England and the United States.

Born: 1954
Education: Medical doctor, PhD in clinical pharmacology at the Karolinska Institutet.
Other current assignments: Eugen Steiner is CEO and chairman in NVC Holding AB and CEO of Glionova AB. Eugen Steiner is also board member of Apotek Produktion & Laboratorier AB, Inbox Capital AB, Stifelsen Forska!Sverige, Stockholm School of Entrepreneurship and Setraco AB.
Prior assignments (past five years): Eugen Steiner has during the past five years been CEO and board member substitute of Optivy Sweden AB, CEO of Nordic Vision Clinics AS and chairman of LTB4 Sweden AB, CC10 Sweden AB and PanSyn Sweden AB. Eugen Steinar has also been board member of Hanza Holding AB, Alba Therapeutics Inc., Biostratum Inc., Nephrogenex Inc., Globen Ögonklinik AB, Praktikertjänst Aktiebolag, MD Internationel AB and Setraco AB.
Holdings in the Company: Eugen Steiner owns, through Setraco AB, 40,000 B-shares in the Company. Eugen Steiner has also acquired 1,818 call options from the Main Shareholders. The options entitle to the acquisition of 27,270 B-shares in the Company.

Independent in relation to BioArctic, its senior management and major shareholders.

Holdings in BioArctic AB as of October 18, 2017.